DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/2050
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJha, Prabhat N.-
dc.contributor.authorMurugesan, Sankaranarayanan-
dc.date.accessioned2021-09-17T04:39:40Z-
dc.date.available2021-09-17T04:39:40Z-
dc.date.issued2017-02-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0045206816300888?via%3Dihub#!-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/2050-
dc.description.abstractIn the present study, we have reported synthesis and biological evaluation of a series of fifteen 1-(thiophen-2-yl)-9H-pyrido[3,4-b]indole derivatives against both promastigotes and amastigotes of Leishmania parasites responsible for visceral (L. donovani) and cutaneous (L. amazonensis) leishmaniasis. Among these reported analogues, compounds 7b, 7c, 7f, 7g, 7i, 7j, 7m, 7o displayed potent activity (15.55, 7.70, 7.00, 3.80, 14.10, 9.25, 3.10, 4.85 μM, respectively) against L. donovani promastigotes than standard drugs miltefosine (15.70 μM) and pentamidine (32.70 μM) with good selectivity index. In further, in-vitro evaluation against amastigote forms, two compounds 7g (8.80 μM) and 7i (7.50 μM) showed significant inhibition of L. donovani amastigotes. Standard drug amphotericin B is also used as control to compare inhibition potency of compounds against both promastigote (0.24 μM) and amastigote (0.05 μM) forms.en_US
dc.language.isoenen_US
dc.publisherElsieveren_US
dc.subjectBiologyen_US
dc.subjectPharmacyen_US
dc.subjectLeishmaniasisen_US
dc.subjectPromastigoteen_US
dc.subjectAmastigoteen_US
dc.subjectβ-carbolineen_US
dc.titleSynthesis and in-vitro anti-leishmanial activity of (4-arylpiperazin-1-yl)(1-(thiophen-2-yl)-9H-pyrido[3,4-b]indol-3-yl)methanone derivativesen_US
dc.typeArticleen_US
Appears in Collections:Department of Biological Sciences

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.